ArticleFASEB bioAdvances2025
Furin inhibits HSCs activation and ameliorates liver fibrosis by regulating PTEN-L/PINK1/parkin mediated mitophagy in mouse.
Article in FASEB bioAdvances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Pharmacological Effects and Proposed Mechanisms ofLife (Basel, Switzerland) · 2026Review
- Multiplexed targeted mRNA profiling of alcohol-related liver disease reveals stage-specific dysregulation of signaling pathways.Molecular biology reports · 2026Article
- Resveratrol ameliorates CClMolecular biology reports · 2025Article
- Mitophagy as a pivotal axis in non‑alcoholic fatty liver disease: From pathogenic mechanisms to therapeutic strategies (Review).Molecular medicine reports · 2025Review
- Furin inhibits HSCs activation and ameliorates liver fibrosis by regulating PTEN-L/PINK1/parkin mediated mitophagy in mouse.FASEB bioAdvances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic Stellate cells (HSCs) play an important role during liver fibrosis progression; more and more evidence indicates that mitophagy greatly regulates HSCs activation. HSCs mitophagy mainly depends on the classical PINK1/Parkin pathway, which can be strongly regulated by phosphatase PTEN-long (PTEN-L). PTEN-L can be cleaved by Furin that leading to functional changes in the tumor regulation process. However, the impact of the interaction between Furin and PTEN-L on HSCs mitophagy remains unclear. Therefore, this study aims to explore the role of Furin in HSCs activation and liver fibrosis and its potential mechanisms. Our results revealed that Furin expression was obviously up-regulated during HSCs activation and mice liver fibrogenesis. We also found that the activation of primary HSCs can be inhibited by Furin treatment in vitro. Besides, functional studies showed that LX-2 cell proliferation and migration were obviously inhibited by Furin treatment. Further studies showed that mitochondrial membrane potential (MMP) was significantly reduced by Furin treatment, and the knockdown of PTEN-L expression caused similar effects. These results demonstrated the role of Furin in promoting HSCs mitophagy but leading to inhibition of HSCs persistent activation. Furthermore, we constructed a liver fibrosis mouse model by CCl4-induced method and found that forced expression of Furin caused alleviation of liver fibrosis in CCl4-induced mice. Our findings provide a new clue for understanding liver fibrogenesis and highlight the therapeutic potential of Furin for hepatic fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.